FY2027 EPS Estimate for Oncolytics Biotech Lifted by Analyst

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Investment analysts at HC Wainwright upped their FY2027 EPS estimates for Oncolytics Biotech in a research note issued to investors on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.08) for the year, up from their previous estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2028 earnings at $0.39 EPS.

Several other analysts have also recently weighed in on ONCY. Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. Royal Bank of Canada reduced their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Maxim Group reduced their target price on shares of Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday. Three equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Oncolytics Biotech currently has an average rating of “Buy” and an average target price of $4.00.

Oncolytics Biotech Stock Performance

NASDAQ ONCY opened at $0.62 on Thursday. The firm has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $0.92. Oncolytics Biotech has a one year low of $0.58 and a one year high of $1.53. The firm has a market cap of $53.27 million, a price-to-earnings ratio of -2.31 and a beta of 1.18.

Institutional Trading of Oncolytics Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC raised its holdings in Oncolytics Biotech by 15.0% during the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after purchasing an additional 26,069 shares in the last quarter. Vantage Point Financial LLC acquired a new stake in Oncolytics Biotech during the fourth quarter worth approximately $27,000. Geode Capital Management LLC raised its holdings in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after purchasing an additional 24,997 shares in the last quarter. National Bank of Canada FI raised its holdings in Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after purchasing an additional 42,955 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Oncolytics Biotech in the 4th quarter valued at $90,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.